Dobutamine Stress Echocardiography in Cardiac Resynchronization Therapy (CRT) Patients Selection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

270 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-07-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

While cardiac resynchronization therapy (CRT) has a well demonstrated therapeutic effect in selected patients with advanced heart failure (HF) on optimized drug therapy, non-responder rate remains high. The low-dose dobutamine stress-echo (DSE) test to predict positive response to CRT (LODO-CRT) trial is designed to improve patient selection for CRT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New Three-dimensional Methods of Analysis for the Detection of Coronary Artery Disease by Dobutamine Stress Echocardiography

NCT02240745

Coronary Artery Disease Echocardiography, Stress

COMPLETED

Myocardial Perfusion, Coronary Flow Reserve and Kinetic Analysis During Dobutamine Stress Echocardiography

NCT03996499

Coronary Disease

UNKNOWN NA

Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease

NCT00001889

Coronary Disease

COMPLETED PHASE2

Right Ventricular Contractile Reserve in HF

NCT05797584

Heart Failure

RECRUITING NA

Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG

NCT00310622

Myocardial Ischemia

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

LODO-CRT is a multicenter prospective study enrolling HF patients with conventional indication to CRT (symptomatic stable NYHA class III-IV on optimized drug therapy, QRS≥120 msec, left ventricular (LV) dilatation, LVEF≤35%) is designed to assess the predictive value of LV contractile reserve (LVCR), determined through DSE, in predicting CRT response during follow-up. Assessment of CRT effects will follow two sequential phases: in phase 1 CRT response end-point is defined as left ventricular end-systolic volume (LVESV) reduction ≥ 10% at 6 months; in phase 2, both LVESV reduction and clinical status via a clinical composite score will be evaluated at 12 months follow-up. Predictive value of LVCR will be compared to other measures, such as LV dyssynchrony measures, through adjusted multivariable analysis. For the purpose of the study, target patient number is 270 patients (with 95% confidence, 80% power, α≤0.05).

LVCR assessment, using low-dose DES test, should effectively predict positive response to CRT both in terms of the reverse remodeling process as well as favorable long-term clinical outcome. Moreover, the predictive value of LVCR will be compared to that of conventional intra-LV dyssynchrony measures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* severe HF despite optimized medical therapy
* NYHA functional class III-IV
* dilated cardiomyopathy of both ischemic and non-ischemic origin
* left ventricular ejection fraction (LVEF) \<=35%
* QRS complex duration ≥120 ms
* normal sinus rhythm.

Exclusion Criteria

* younger than 18 years old
* unstable angina
* acute myocardial infarction
* coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months
* already implanted with a conventional implantable pulse generator or with an implantable cardioverter defibrillator (ICD)
* previously implanted with a CRT device
* chronic permanent atrial arrhythmias

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No